PDCD1LG2 and neoplasm: The expression of PD-L1, PD-L2 and ODC was reduced and the levels of MHCA enhanced after exposure of tumor cells to [pemetrexed + sorafenib], [regorafenib + sildenafil], [neratinib + dasatinib] and [ruxolitinib + neratinib] (Supplementary Figures 19-23).